Episode Details
Back to EpisodesClinical update with Dr. Daniel Griffin
Episode 1140
Published 1 year, 4 months ago
Description
In his weekly clinical update, Dr. Griffin discusses the harms of perpetuating the lab leak hypothesis and the recent ACIP recommendations for the RSV vaccine for those individuals over 60, before reviewing the recent statistics on SARS-CoV-2 infection, treatment guidelines for the different phases of COVID, including vaccines, Pemgarda, early treatment with Paxlovid, remdesivir and molnupiravir, steroids at the right time, anticoagulation support, immune modulation in some cases, and a comprehensive definition of long COVID.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Measles transmission after secondary vaccination failure (Emerg Inf Dis)
- Mpox public health emergency of international concern (WHO)
- First case of new mpox strain outside of Africa (Reuters)
- COVID-19 national trend (CDC)
- COVID-19 deaths (CDC)
- Where to get pemgarda (Pemgarda
- CDC Quarantine guidelines (CDC)
- Early phase of SARs-CoV-2 infection (COVID.gov)
- Individual monoclonal antibodies against SARS-CoV-2 should be used (CID)
- NIH COVID-19 treatment guidelines (NIH)
- Infectious Disease Society guidelines for treatment and management (ID Society)
- Drug interaction checker (University of Liverpool)
- Molnupiravir safety and efficacy (JMV)
- Convalescent plasma recommendation for immunocompromised (ID Society)
- Managing healthcare staffing shortages (CDC)
- Steroids,dexamethasone at the right time (OFID)
-
Listen Now
Love PodBriefly?
If you like Podbriefly.com, please consider donating to support the ongoing development.
Support Us